Background
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide [
1]. Except for the most characteristic finding, that is glomerular mesangial area deposition of IgA, a considerable proportion of IgAN patients present with histological vasculitic/crescentic lesions in glomeruli, accompanied by distinct neutrophils and/or monocytes infiltration, indicating the activation of vascular inflammation in IgAN [
2]. Clinically, many patients with IgAN suffer hypertension at a relative young age, and some present with secondary malignant hypertension. In China, IgAN was reported as one of the major causes of secondary malignant hypertension, accounting for one-third of all secondary causes and 40% of glomerular causes [
3,
4]. Although clinical and histological observations strongly indicated the involvement of vascular injury in IgAN, the pathogenesis of the vascular injury in IgAN is still unknown.
Vascular cell adhesion molecule 1 (VCAM-1) is endothelial ligand for integrins expressed on leukocytes and platelets, with the function of facilitation endothelial adhesion of circulating leukocytes. The endothelial expression of VCAM-1 is increased in response to inflammatory cytokines [
5]. And the soluble ectodomain of VCAM-1 (sVCAM-1) is proteolytically released from the endothelial cell surface into the circulation upon endothelial activation and injury. Elevated plasma sVCAM-1 level was reported in many diseases, such as coronary and peripheral atherosclerosis, diabetes mellitus, systemic lupus erythematosus, Crohn's disease and so on [
6‐
9]. Soluble vascular adhesion molecule-1 is now a well-proven marker for endothelial injury under inflammatory processes.
In patients with chronic kidney disease (CKD), including IgAN, elevated plasma sVCAM-1 level was also observed and reported to be associated with impaired renal function [
10‐
13]. But most studies were unable to state the major cause of high plasma levels of sVCAM-1, which could be either explained by increased production or decreased clearance. Recently, A.E.M. Stinghen et al. reported that exposure of endothelial cells to uremic plasma resulted in a time- and CKD-stage-dependent increased expression of sVCAM-1, suggesting a link between vascular activation, systemic inflammation and uremic toxicity [
14]. IgA nephropathy, a study is needed to explore the cause of high plasma levels of sVCAM-1 and its association with vascular inflammation.
In the present study, we investigated the association of sVCAM-1 with clinical and pathological characteristics in patients with IgAN, and further detected the effect of IgA1 molecules on sVCAM-1 production by cultured endothelial cells in vitro to explore the mechanism of vascular inflammation in IgAN.
Methods
Study population
In the present study, a total of 382 subjects were enrolled, including 327 IgAN patients and 55 healthy volunteers with normal urine analysis and blood pressure. Diagnoses of IgAN were biopsy proven and confirmed by granular deposition of IgA in the glomerular mesangium by immunofluorescence detection, as well as by the deposition of electron dense material in mesangial ultra-structural examination. Patients with Henoch-Schonlein purpura, systemic lupus erythematosus, and chronic hepatic diseases were excluded by detailed clinical and laboratory examinations. In addition, 19 patients with minimal change disease (MCD), 30 with membranous nephropathy (MN) and 25 with lupus nephritis were recruited as control patients with other glomerular injury.
On the morning of renal biopsy and the inclusion in the study, plasma (EDTA) from patients and healthy volunteers was collected, divided into aliquots, and stored at −80°C pending the measurement of sVCAM-1. Clinical manifestations at the time of renal biopsy, including serum IgA level, serum creatinine level, 24 hours urine protein excretion, history of hypertension and history of gross hematuria were collected from the clinical record. The glomerular filtration rate (GFR) of IgAN patients was calculated by the Modified Glomerular Filtration Rate Estimating Equation for Chinese [
15]. Histologically, the Oxford classification was used for evaluating the pathological lesions [
16]. Additionally, we used two indices to grossly distinguish the active and chronic glomerular lesion, which were Active Crescentic Lesion Percentage (ACLP) and Chronic Glomerular Lesion Percentage (CGLP). ACLP included the glomerular bearing cellular crescents, fibrocellular crescents and fibrinoid necrosis. CGLP included the glomerular having global sclerosis, segmental sclerosis and fibrous crescents.
The protocol for this study was approved by the Medical Ethics Committee of Peking University and informed written consent for this study was obtained from every participant.
Detection of plasma sVCAM-1
Plasma sVCAM-1 levels were determined using commercial ELISA kits according to the manufacturer’s specifications (R&D Systems, Minneapolis, MN, USA).
Isolation of human plasma IgA1
Whole IgA1 was isolated by jacalin affinity chromatography from plasma as previous described [
17]. In the present study, another small population, including 12 biopsy approved IgAN patients and 12 healthy controls, was used for IgA1 isolation. Plasma from the 24 individuals was introduced to jacalin affinity chromatography, one by one. Briefly, 3ml plasma from every subject were diluted 1:3 with 0·01 mol/l phosphate buffered saline (PBS), filtered through a 0.22 um Corning syringe filter (Corning Glass Works, Corning, NY, USA) and then applied to a jacalin column, which was prepared with commercially available jacalin immobilized on cross-linked 4% beaded agarose (Pierce Chemical Company, Rockford, IL, USA) with an IgA1 binding capacity of more than 2 mg/ml. The column was equilibrated with 0.01 mol/l PBS and IgA1 was eluted with 0.1 mol/l melibiose (Sigma, St. Louis, MO, USA) in 0.01 mol/l PBS. The eluted sample concentration and removal of melibiose were performed by pressure ultrafiltration using Vivaspin (Cat No: VS2021, Sartorius, Goettingen, Germany). The total protein concentrations of isolated IgA1 samples from the 24 individuals were tested using
DC Protein Assay (Bio-Rad, Hercules, CA, USA). IgA1 was then aliquoted and stored at −80°C pending cell culture experiments.
Culture of endothelial cells with IgA1
Primary Human Umbilical Vein Endothelial Cells (HUVECs) and all the cell culture media, fetal bovine serum, supplements and extra cellular matrix were purchased from ScienCell Corporation (ScienCell, Carlsbad, CA, USA). Cells were cultured according to the manufacturer’s specifications, in Endothelial Cell Medium (ECM) supplemented with Endothelial Cell Growth Supplement (EsCGS), 5% fetal bovine serum, penicillin G (100 U/ml) and streptomycin (100 U/ml) at 37°C in a humidified 5% CO2 incubator. HUVECs were seeded into 24-well plates precoated with 1 ug/cm2 Poly-L-Lysine (PLL) before experiment. After 12 h of serum starving, HUVECs were treated with 400 ug/ml whole IgA1 from 24 individuals, including 12 IgAN patients and 12 healthy controls (we did not pool isolated IgA1 from different IgAN patients and healthy controls together). For dose-dependent assay, 25-400 ug/ml whole IgA1 from one IgAN patient were used. For time-dependent assay, HUVECs were treated with 200 ug/ml whole IgA1 from one IgAN patient for 6–48 hours.
Detection of supernatant sVCAM-1
Supernatant samples were separated from culture after 48h of incubation (except for time-dependent assay, in which 6-48 h were used) and were stored at −80°C until assay. Supernatant sVCAM-1levels were measured by ELISA as described above.
Statistical analysis
Descriptive statistical analyses were performed with SPSS10.0 software (SPSS Inc., USA). Continuous variables were compared by unpaired Student’s t test or ANOVA (ANalysis Of VAriance between groups). Dichotomous and polychromous data were analyzed by the χ2 test. Correlations were performed by the Spearman rank test (ρ). Results are expressed as means ± SD. A p value of less than 0.05 was considered statistically significant.
Discussion
Patients with IgA nephropathy presented with variable clinical findings, histological impairments and long-term renal outcomes [
18]. In the present study, we enrolled 327 patients with IgAN. Among them, 37.9% patients presented with clinical hypertension at the time of renal biopsy, which was well-approved to be an independent risk factor for long-term renal outcome [
19,
20]; and 56.9% patients presented with histological endocapillary hypercellularity, according to Oxford classification. This supported previous observations that a great mass of IgAN patients suffered vascular injury [
21]. When we used sVCAM-1 as the marker for vascular injury, especially inflammation injury, results showed that patients with IgAN had significantly elevated plasma sVCAM-1 compared to healthy controls, which was in accordance with previous reports in other IgAN patients’ cohorts [
11]. Similarly, in patients with lupus nephritis, in which condition vascular injury were commonly reported, sVCAM-1 levels were also significantly higher. But in some other glomerular injury conditions, such as MCD and MN, patients showed comparable sVCAM-1 levels to healthy controls. Therefore, we regarded sVCAM-1 as an indicator to vascular injury other than glomerular injury.
Hypertension is a well accepted clinical finding for vascular injury, but still over 70% patients in our present study did not have this obvious symptom for vascular injury. Although without hypertension, they also showed significantly higher plasma sVCAM-1 compared to healthy controls, while the patients with hypertension presented with even higher plasma sVCAM-1. From above findings, we suggested that plasma sVCAM-1 as another marker for vascular injury, except for clinical hypertension, and IgAN patients suffered vascular injury are likely underestimated.
In addition, we described the significant association between plasma sVCAM-1 level and clinical findings, including eGFR and urinary protein excretion. D’Amico G has already came to the concordance that impairment of renal function, severe proteinuria, and arterial hypertension were the strongest and more reliable clinical predictors of an unfavorable outcome after critical analysis of results of 30 studies [
22]. Since plasma sVCAM-1 level in patients with IgAN associated with all the three risk factors, we speculated the patients had higher plasma sVCAM-1 levels would be in more severe clinical states of IgAN.
Accordingly, we found the significantly different plasma sVCAM-1 level among patients with different tubular atrophy/interstitial fibrosis lesion judged by Oxford classification, an independent predictor of long-term renal outcome measured by multivariate analysis. This result indicated that plasma sVCAM-1 level in patients was a marker not only for severe clinical state but also for severe histological lesion of IgAN.
Oxford classification was derived from a group of IgAN patients without most acute and rapidly progressive disease courses and more than 50% of them without crescent, but many of our IgAN patients in the present study had crescentic lesion in the glomeruli. Therefore, we used two variables, Active Crescentic Lesion Percentage (ACLP) and Chronic Glomerular Lesion Percentage (CGLP), to roughly distinguish the acute and chronic histological lesions. We surprisingly found that only ACLP was significantly associated with plasma sVCAM-1 level, not CGLP. It is important for us to point out that plasma sVCAM-1 level was a marker for acute crescentic lesion in patients with IgAN. Crescentic lesion is actually a kind of glomerular vascular inflammation, so we considered elevated plasma sVCAM-1 level in patients with IgAN can at least partly ascribed to glomerular vascular inflammation lesion.
Furthermore, we wanted to explore the reason of the elevated sVCAM-1 in IgAN. In recent years, lots of efforts have been made to uncover the pathogenesis of IgAN, and some significant progress has been achieved in this field [
23‐
25]. Increasing evidences indicated abnormal IgA1 molecules from IgAN patients to be the initial factor to induce glomerular mesangial cells proliferation and secondary podocytes and tubular epithelial cells injury [
26‐
29]. Regarding to endothelial cells, less evidence was available. We hypothesized that abnormal IgA1 molecules from IgAN patients had unique activity to promote sVCAM-1 expression from endothelial cells. In order to exclude other reasons induced sVCAM-1 elevation in IgAN patients, such as inflammation induced increased production by inflammatory cells and eGFR induced decreased clearance, an in vitro cell model was used. In the present study, we inferred that IgA1 molecules from IgAN patients could promote sVCAM-1 expression of endothelial cells for the following three evidences: (1) the same amount of IgA1 from IgAN patients showed a tendency to increase endothelial sVCAM-1 expression; (2) patients with IgAN presented with higher levels of IgA1 compared to healthy controls; (3) IgA1 induced the sVCAM-1 increasing from HUVECs in dose-dependent manner. However, it was very possible that many other factors, like inflammatory cells activation and decreased clearance due to impaired renal function were also contributed to elevated sVCAM-1 in IgAN patients, which we could not determine from present study.
Competing interests
The authors have declared that no competing interests exist.
Authors’ contributions
LZ participated in the design of the study, carried out the molecular biological and cell biological studies and drafted the manuscript. SS carried out the pathological classification. LL recruited patients and participated in the ELISA detection. JL recruited patients and performed the statistical analysis. HZ conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.